Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Launched by INVESTIGACION BIOMEDICA PARA EL DESARROLLO DE FARMACOS S.A. DE C.V. · May 27, 2020

Keywords

ClinConnect Summary

In late 2019, an unidentified viral pneumonia was detected in Wuhan, China. Later, it was declared that it was pneumonia due to a new coronavirus. The World Health Organization (WHO) officially called it COVID-19 disease (Xie and Chen 2020).

Ivermectin is a broad-spectrum antiparasitic agent, developed to combat parasitic worms in veterinary use and in human medicine. This compound has been used orally in humans to treat filariasis, but is also effective against other worm-associated infections, as well as parasitic skin diseases and insect infections. It is approved for human use in sever...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of acute severe respiratory syndrome due to SARS-CoV-12 coronavirus infection defined by RT-PCR.
• • Asymptomatic, or with mild symptoms who are taking outpatient treatment of the disease.
• • Signed Informed Consent.
• Exclusion Criteria:
• • 1. Patients with severe disease COVID-19.
• • 2. Positive to proof of infection by some other virus such as influenza H1N1, SARS, etc.
• • 3. Recurrent urinary tract infections.
• • 4. Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)\> 5 times above its normal limits.
• • 5. Pregnant or lactating patients
• • 6. Patients receiving antihypertensive medication verapamil, the immunosuppressant cyclosporin A and / or the antipsychotic trifluoperazine.
• • 7. Patients with a known allergy or hypersensitivity to dewormers.
• • 8. Patients who are using an antioxidant supplement.
• • 9. Patients with a history of filariasis, strongyloidiasis, scabies, river blindness, or any parasitic disease in the last twelve months.